BOTHELL, Wash.--(BUSINESS WIRE)--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it will hold a conference call on Monday, September 24, to discuss the results from the pivotal Phase 3 clinical trial of TOCOSOL® Paclitaxel, the Company’s lead oncology product candidate.
